158 related articles for article (PubMed ID: 16531969)
1. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
Byrnes V; Afdhal N; Challies T; Greenstein PE
Ann Hepatol; 2006; 5(1):56-9. PubMed ID: 16531969
[TBL] [Abstract][Full Text] [Related]
2. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Tamura S; Warabi Y; Matsubara S
J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
4. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.
Tremlett HL; Oger J
Mult Scler; 2004 Jun; 10(3):298-301. PubMed ID: 15222695
[TBL] [Abstract][Full Text] [Related]
5. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.
Duchini A
Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585
[No Abstract] [Full Text] [Related]
7. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.
Tremlett H; Oger J
J Neurol; 2004 Nov; 251(11):1297-303. PubMed ID: 15592724
[TBL] [Abstract][Full Text] [Related]
8. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis.
Bonaci-Nikolic B; Jeremic I; Andrejevic S; Sefik-Bukilica M; Stojsavljevic N; Drulovic J
Lupus; 2009 Jan; 18(1):78-80. PubMed ID: 19074173
[TBL] [Abstract][Full Text] [Related]
9. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
Christopher V; Scolding N; Przemioslo RT
J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
[No Abstract] [Full Text] [Related]
10. Interferon-beta treatment in patients with childhood-onset multiple sclerosis.
Mikaeloff Y; Moreau T; Debouverie M; Pelletier J; Lebrun C; Gout O; Pedespan JM; Van Hulle C; Vermersch P; Ponsot G
J Pediatr; 2001 Sep; 139(3):443-6. PubMed ID: 11562627
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hepatitis-like reaction developing in a patient treated with interferon-β1a.
Mishra A; Guindi M; Kandel G; Streutker CJ
Histopathology; 2015 Mar; 66(4):605-7. PubMed ID: 24796493
[No Abstract] [Full Text] [Related]
12. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
13. Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.
Kumasaka R; Nakamura N; Shirato K; Fujita T; Murakami R; Shimada M; Nakamura M; Osawa H; Yamabe H; Okumura K
Clin Exp Nephrol; 2006 Sep; 10(3):222-5. PubMed ID: 17009081
[TBL] [Abstract][Full Text] [Related]
14. Arthritis during interferon beta-1b treatment in multiple sclerosis.
Altintas A; Alici Y; Melikoğlu M; Siva A
Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
[TBL] [Abstract][Full Text] [Related]
15. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
Expert Opin Drug Saf; 2014 Oct; 13(10):1305-17. PubMed ID: 25134421
[TBL] [Abstract][Full Text] [Related]
16. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
17. [Current status of interferon beta-1b in multiple sclerosis therapy].
Hartung HP
Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
[TBL] [Abstract][Full Text] [Related]
18. [Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report].
Cruz BA; Queiroz ED; Nunes SV; Cruz Filho A; Campos GB; Monteiro EL; Crivellari H
Arq Neuropsiquiatr; 2000 Jun; 58(2B):556-9. PubMed ID: 10920422
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
Kocer B; Nazliel B; Oztas M; Batur HZ
Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
[No Abstract] [Full Text] [Related]
20. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L; Neves M; Cardoso E; Melo A
J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
